These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6795909)

  • 21. Effects of encainide on the inducibility of ventricular arrhythmia in normal anesthetized dogs.
    Zeng FD; Nattel S
    J Tongji Med Univ; 1986; 6(1):60-6. PubMed ID: 3086567
    [No Abstract]   [Full Text] [Related]  

  • 22. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug.
    Berchtold-Kanz E; Schwarz G; Hust M; Nitsche K; Just H
    Clin Cardiol; 1984 Sep; 7(9):493-7. PubMed ID: 6442223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
    Thale J; Klein H; Shanks RG; Bender F
    Z Kardiol; 1985 Apr; 74(4):220-7. PubMed ID: 2408392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spontaneous sustained ventricular tachyarrhythmias during treatment with type IA antiarrhythmic agents.
    Kudenchuk PJ; Kron J; Walance C; McAnulty JH
    Am J Cardiol; 1990 Feb; 65(7):446-52. PubMed ID: 2305683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-arrhythmia effect of long-term encainide in chronic ventricular extrasystole].
    Dumoulin P; Jaillon P; Kher A; Poirier JM; Cheymol G; Valty J; Flammang D; Coumel P; Medvedowsky JL; Barnay C
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():105-9. PubMed ID: 2420299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog.
    Dawson AK; Roden DM; Duff HJ; Woosley RL; Smith RF
    Am J Cardiol; 1984 Sep; 54(6):654-8. PubMed ID: 6475789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Encainide for refractory ventricular tachyarrhythmia.
    Chesnie B; Podrid P; Lown B; Raeder E
    Am J Cardiol; 1983 Sep; 52(5):495-500. PubMed ID: 6193701
    [No Abstract]   [Full Text] [Related]  

  • 30. Antiarrhythmic efficacy of encainide and quinidine: validation of a model for drug assessment.
    Sami M; Harrison DC; Kraemer H; Houston N; Shimasaki C; DeBusk RF
    Am J Cardiol; 1981 Jul; 48(1):147-56. PubMed ID: 6787910
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs.
    Kerr MJ; Allen JD; Harron DW; Shanks RG
    J Cardiovasc Pharmacol; 1985; 7(3):449-57. PubMed ID: 2410673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA; Gillette PC; Benson DW
    J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms.
    Rinkenberger RL; Prystowsky EN; Jackman WM; Naccarelli GV; Heger JJ; Zipes DP
    Am Heart J; 1982 Feb; 103(2):177-84. PubMed ID: 6798855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
    Caron JF; Libersa CC; Kher AR; Kacet S; Wanszelbaum H; Dupuis BA; Poirier JM; Lekieffre JP
    J Am Coll Cardiol; 1985 Jun; 5(6):1457-63. PubMed ID: 2582017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience of encainide (MJ 9067): a new anti-arrhythmic drug.
    Kesteloot H; Stroobandt R
    Eur J Clin Pharmacol; 1979 Nov; 16(5):323-6. PubMed ID: 93050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiology, hemodynamic and arrhythmia efficacy model studies on encainide.
    Gomoll AW; Byrne JE; Antonaccio MJ
    Am J Cardiol; 1986 Aug; 58(5):10C-17C. PubMed ID: 3092614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Encainide: a new antiarrhythmic agent.
    Wehmeyer AE; Thomas RL
    Drug Intell Clin Pharm; 1986 Jan; 20(1):9-13. PubMed ID: 3080301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Encainide. A review of its pharmacological properties and therapeutic efficacy.
    Brogden RN; Todd PA
    Drugs; 1987 Nov; 34(5):519-38. PubMed ID: 3121275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sinus node dysfunction and sudden cardiac death following treatment with encainide.
    Lemery R; Talajic M; Nattel S; Theroux P; Roy D
    Pacing Clin Electrophysiol; 1989 Oct; 12(10):1607-12. PubMed ID: 2477816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.